D e l~a t . l~r~c~~t ul'l'utliatrics, U~~i v c r s~t y i~l ' A~. k i~~~s : i s f o r Mciliciil S c i c~~c c s ant1 A r k a n s a s C l~i l d r c r~'~ I I o s~~i t n l , 1.ittle I t r~c k , A l t 9 7 2 0 2 , ant1 G c r~e r i t c c l~, Inc., S o u t l~ S a n F r a n c i s c o , C A 9 4 0 5 0 , U S A I n t h e 30 y e a r s t h a t g r o w t l~ I~o r r r~o n c ( G I I ) h a s b e e n u s e t l t o treat G I 1 deficiency, dose f r e q i c e n c y h a s c h a n g e d c o n s i i l c r a b i y . E a r l y s t u d i e s d c m o r i s t r a t e d i l n p r o v e t l r e s p o n s e b y i n c r e a s i n g tlosc f r e q u e n c y Cram 2 t o 3 tittles per w c c k ('l'lW). G I 1 a~l m i n i s l r a t i o n ill t i l e N a t i o~i a l Cooperal.ive G r o w t h S t t~t l y ( N C G S ) [ l a l a base c l~a r~g c t l f r o m 9 7 % T I W 1 9 8 7 to 8 5 % dirily (6-7 i n j e c t i o n s p e r w c c k ) irr 1 9 9 2 . W e h a v e c a l c~l l a t c i l g r o w t h r a t e s f o r t l~o s c n a i v e p a l i c n t s i n t h e N C G S d a t a base will1 i d i o p a t h i c growl11
h o r l n o n e d e f i c i e n c y w l r o r e c e i v e d G I 1 ~l a i l y ( N = 1 0 0 ) o r T I W ( N = 1 9 5 ) . 'I'lie g r o u p s d i d n o t d i f f e r s t a t i s t i c a l l y i n L c r~r~s o f a g e (7.1 y r tlaily; 6.7 y r T I W ) , boric age tlclay (2.1 yr ilaily; 2 . 3 y c i l r s T I W ) , r r i a x i n i n~n s t i m~t l a t c d G I 1 (5.1 daily; 4.5 n g /~n l 'I'IW) o r p r c t r c a t~n c n t g r o w t h r a t e (3.9 c m / y r daily; 4.2 c m l y r TIW). D i f T e r c n c c s i n g r o w t l~ rates f o r the t w o g r o u p s w e r e m o s t d r a m a t i c ill t l~c f i r s t year o f tlrcral)y, (tlaily 1 1 . 0 crn vs. T I W 9 . 4 c m (1) < 0.005)). I t a l e s r e r n a i n c t l t l i f f c r e r~t i n t h e s c c o n i l y e a r (daily 8.3 c m , TIW 7 . 5 c m ( p < 0.005)). B o n e age a t l v a n c c m e n t was 1.3 yr (daily) ant1 1.1 yr ( T I W ) (11s). T h u s , w h i l e t h e a t l v a n t a g c o f tlaily o v e r T I W irljection f r c c l u c n c y i s m o s t t l r a r n a t i c t l u r i n g t h e f i r s t y e a r , d a t a f r o m t l r c N C G S s l~o w t l~a t t l t i s a i l v a n t a g e o o r r t i~~i~e s f o r at 1e;lsl t w o y e a r s i r~ n a i v e g r o w t h 11urn1o11c t l c l i c i c l~l ~~i l t i e~~l s . 
e l s i n a l l c h i l d r e n v i t 1 1 s h o r t s t e t u r c r i i~o v c r c b e i n c ! e v a l u a t e d f o r p o s s i b l e g r o w t h h o r m o n e d e f i c i e n c y v i t h a n a r q i n i n e / g l r l c a q o n s t i m u l a t i o n t e s t . L i p i d l e v e l s w e r e d e t e r m i n e d i n 1 1 0 f a s t i n g c h i l d r e n a n d 3 3 o f t h e s e c h i l d r e n v e r e P o u n d t o lie g r o v t h h o r m o n e ( G H ) d e f i c i e n t ( h u t e u t h y r o i d ) . T h e m e a n c h o l e s t e r o l v a l u e s w e r e n o t s i g n i f i c a n t l y d i f f e r e n t b e t w e e n t h e c o n t r o l a n d GI1 d e f i c i e n t g r o u p s ( 1 7 1 . 0 r n g / d l v s . 1 0 4 . Two hundred thirty-two feniales with Turner's syndrome, diagnosed by knryotype, were enrolled in Lhis ungalng, age-str;ltified, double-blinded, r;lndom~red, parallel, placebo-controlled (18 months1 to dose response study conducted by 50 investigational sites in the United States. Patients were randomized to one of five treatment groups: 0.09 m g k g t h r~c e weekly w~t h or wlthout dally estrogen, 0 12 mgkg thrice weekly with or without daily estrogen, or placebo injections wlth placebo tablets. After 18 months, sign~ficant diflerences !by rank based a n a l y s~s ) were observed between the least responsive treatment group and the remaining four treatment groups for mean ehanga ~n h e~~h t , Lyon helght standard d c v > a t~o n score (SDS) and erowth rnte Additionallv. the icast resvonsive treatment erouo least responsive treatment group (dunrig the first 1 8 months) reniained statistic;~lly different from the other treatment e r o u~s for mean chance in h e~c h t for the first 36 ULOI.II>S \VCP 11.c c c i~r c I), I I V~V i l~t \~t n , t r r , $< ~i l i I ? ~~i l~o u t e.tr,:~ :.!u,es 3 ilgn!fis:ll 1 lllcre
) h o w e v e r , a d i s t i n c t h i m o d a l p a t t e r n w a s n o t e d f o r t h e GR d e f i c i e n t g r o u p w i t h 1 5 % o f t h e l e v e l s 1 9 0 a s o p p o s e d t o 26% f o r t h e n o r m a l s h o r t s t a t u r e g r o u p . H y p e r c h o l e s t e r o l e m i a ( 0 0 ) rvas p r e s e n t i n 1 % o f t h e Gli d e f i c i e n t c h i l d r e n . T h e c h o l e s t e r o l l e v e l s d i d n o t c o r r e l a t e v i t h t h e p e a k g r o i r t h h o r m o n e r e s p o n s e o r p r e t r e a t m e n t g r o w t h v e l o c i t y . T h i s s u b s e t o f GH d e f i c i e n t c h i l d r e n x i t h h y p e r c h o l e s t e r o l e m i a n e e d s t o b e c h a r a c t e r i z e d r r i r t h e r a n d s u p p o r L s t h e r o l e o r Gll i n m o d u l a t i n g l i p i d m e t a b o l i s m .

THREE YEAR EFFICACY RESULTS O F A PLACEBO-CONTROLLED T O DOSE RESPONSE STUDY O F IIUMAN G R O W I I IIORMONE
In g r~\ . l h r.tlc I.(. j h l . .?(I 1 Cn,lrlnP 111 1-~1gI:1 .!fllr '3" 18) n1I.s. howtvcr lhe overall ~f l e c i i n fi~l;l hetght rttl,t u n i i~ bc q~u n t~f i e d 'lhc >ncrdasl; in mean L~O I SDS dlnn.: rhr I I I I I I : ,~ i d ~t . . l ) t n i SCS.I. l r r the I<:t*t T P C I I J I I~I \ P t r d a t n i~n t group suggesis that using Lyon's dntn a s ;i histor~cnl control may over estln,;~te the ultimate effect of growth hormone on Rnnl h e~g h t for U.S. Turner syndrome patients.
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THE EFFECT OF STANOZOLOL OK F I S A I~ IIEIGIIT nsn SKCLFYAI. I;~,VTURIITIOI':
Ihl TURNER'S SYNDItOMP. 11 S a t o h " I1 Yono". 1' I'anoka", A Tanzie'" a n d I ll~hl*'. " E n d o c r i n e R e s e a r c l i 1.aboraLory. N a t~o n a l Children's 0 53 l ' h c r e w e r e n o s l~n l i i c a n t ( i l i i r r c n c o s lri i~n a i h e~g h t a n d A llSOS bcLwccrl t h o p a t i e n t s w~t h 45, X k<lryoLyp<! in-1 l) a n ? i l i o s e w i t h o t h e r -chr.omosornal variants (rl=24) l'tlc l l r l a l h c~y h t ir, SI;U firour, Gronlla Vt.locllv (GV) In rc.;pc,nrc 10 rccosll>innnl (;I1 11, \>IS rsd1,rr.d ~\i,>g li1i;S dnla bme. ICIiU n u , lbated on c r~~~l c~l ccilerld : \l>c,rl $lulc~r?, hr&v ~~O L , I I , velorlly; OH peak ra\potl\o "1 2 prllvorull>c Icrt\ btll?bl 10 nalnll; tl8)rc1ld and udresul atulus were bawd on rllllvei~llc~r~ul liormo!lol sv:liualllls (Ic~nl u\,r)\).Org.t~~lc (;IIIJ v u \ rulad uul by brain iniaglng. 1256 prcpubrrlrl I(;III) (;I1 trcslcd pallrz>l\ I!, KlGS d31il babe Were Ilnnlysed. At \lilrl of KX xnvdii~n C!ITOIIIIIO~!F:~~ Axe (CA) v.1\ 7.3 >csr\, nledlun lhelglll Standard Uevlntion Scorc (SUS) %rl\ -2.7. \Icdl:~t~ nuntbur or lojor~ll,nr
